What Is Selank?
Selank is a synthetic heptapeptide with the amino-acid sequence:
Thr-Lys-Pro-Arg-Pro-Gly-Pro.
It is also known as TP-7.
Selank was developed as a synthetic analogue of tuftsin, a naturally occurring tetrapeptide involved in immune regulation.
Researchers became interested in Selank because modifying the tuftsin structure appeared to produce a peptide with effects extending beyond immunity and into the central nervous system.
Its research history now includes:
anxiety, stress, cognition, memory, neurotransmitter signaling, GABA activity, gene expression, and immune regulation.
That combination makes Selank particularly interesting because it sits at the intersection of neuroscience and immunology.
The FDA’s substance database recognizes Selank as a seven-amino-acid peptide with the sequence TKPRPGP.
Why Are Researchers Interested in It?
Most anti-anxiety drugs work by strongly altering neurotransmission.
That can be effective, but some traditional anxiolytics can also produce sedation, cognitive impairment, tolerance, or dependence.
Selank attracted attention because researchers were looking for a different type of anxiolytic signal.
Instead of simply suppressing nervous-system activity, Selank appears to influence regulatory systems involved in anxiety and stress.
Human and experimental research has explored whether Selank can produce anxiolytic effects while maintaining cognitive function and alertness.
A small published clinical study involving 62 patients with generalized anxiety disorder or neurasthenia compared Selank with the benzodiazepine medazepam and reported similar anxiolytic effects, with additional antiasthenic and psychostimulant effects in the Selank group.
That is one of the reasons Selank remains such an intriguing neuropeptide.
How Does Selank Work?
There does not appear to be one single Selank receptor responsible for all of its effects.
Instead, research suggests Selank may influence several overlapping regulatory systems.
These include:
GABAergic neurotransmission, enkephalin metabolism, serotonin-related signaling, gene expression, and immune signaling.
This is better described as neuromodulation than simple receptor activation.
Rather than acting like a switch that turns one receptor on or off, Selank may alter how several existing signaling systems respond.
Selank & GABA
GABA is the primary inhibitory neurotransmitter in the brain.
It helps regulate neuronal excitability and plays an important role in:
anxiety, relaxation, sleep, stress responses, and emotional regulation.
Benzodiazepines reduce anxiety largely by enhancing signaling through GABA-A receptors.
Selank appears to interact with the GABA system differently.
Research has suggested that Selank may act as an allosteric modulator of GABA-related signaling rather than occupying the classic benzodiazepine binding site.
That distinction is scientifically important.
It may help explain why Selank has been investigated as an anxiolytic without simply reproducing the entire pharmacological profile of a benzodiazepine.
Gene Expression & GABAergic Signaling
Selank research has also examined gene expression.
In animal studies, Selank altered expression of numerous genes associated with neurotransmission.
Researchers found overlap between gene-expression changes produced by Selank and changes associated with GABA exposure.
This supports the idea that Selank may influence the broader GABAergic system rather than acting simply as a direct receptor agonist.
Cell-culture research has produced a more complicated picture, suggesting Selank’s effects can depend on the biological environment and interactions with other signaling molecules.
That complexity is exactly what researchers would expect from a regulatory neuropeptide.
Anxiety Research
Anxiety remains Selank’s best-known research area.
Clinical studies from Russia have investigated Selank in patients with generalized anxiety and related anxiety-spectrum conditions.
One study involving patients with generalized anxiety disorder and neurasthenia reported anxiolytic effects comparable with medazepam.
Another study evaluated Selank alongside phenazepam in people with anxiety-related disorders and investigated whether the peptide could improve treatment response and tolerability.
These studies are relatively small by modern pharmaceutical-trial standards.
Still, they distinguish Selank from peptides whose entire reputation is based only on animal or cell research.
There is genuine human clinical literature behind it.
Stress Resilience
Selank is frequently described as an adaptogenic or stress-regulating peptide.
That language comes from research suggesting its effects extend beyond simply reducing subjective anxiety.
Stress affects:
neurotransmitters, endocrine signaling, immune activity, cognition, sleep, and emotional regulation.
Selank research has examined several of these systems.
This has led researchers to consider whether Selank helps regulate the body’s response to stress rather than simply producing sedation.
That concept—improving adaptation to stress while maintaining function—is central to much of the interest surrounding Selank.
Cognition & Memory
Selank is also frequently classified as a nootropic peptide.
Experimental research has explored effects involving:
learning, memory, attention, cognitive performance, and information processing.
This creates an interesting combination.
Many medications that strongly reduce anxiety can impair memory or concentration.
Selank research instead investigates whether reducing excessive stress signaling might occur alongside preservation—or potentially improvement—of cognitive performance.
That combination of anxiolytic and nootropic research is one of Selank’s defining characteristics.
Anxiety & Cognitive Performance
Stress can significantly interfere with thinking.
Working memory, concentration, decision-making, and recall can all worsen under excessive anxiety.
That means a compound does not necessarily need to directly “boost intelligence” to improve cognitive performance.
If it helps normalize an excessive stress response without causing sedation, cognitive function may improve indirectly.
Selank research is particularly interesting because researchers have investigated both possibilities:
direct neuroregulatory effects and improvements associated with reduced anxiety.
Enkephalins
Another important area of Selank research involves enkephalins.
Enkephalins are naturally occurring opioid peptides involved in:
pain regulation, stress responses, mood, and emotional processing.
They are broken down by enzymes known as enkephalinases.
Research has found that Selank can inhibit enzymatic degradation of enkephalins in experimental systems.
Researchers proposed that preserving endogenous enkephalin signaling may contribute to Selank’s anxiolytic effects.
This provides another possible mechanism beyond GABA.
Serotonin & Monoamine Research
Selank research has also explored neurotransmitter systems involving serotonin and other monoamines.
Serotonin contributes to:
mood, anxiety, sleep, appetite, emotional regulation, and stress responses.
Experimental findings suggest Selank can alter aspects of monoamine metabolism and neurotransmitter signaling.
It does not appear to function simply like an SSRI.
Instead, its effects seem to involve broader regulation of multiple neurological systems.
That is why describing Selank as merely “a peptide version of an anxiety medication” misses much of what makes it interesting.
BDNF & Neuroplasticity
BDNF—brain-derived neurotrophic factor—is deeply involved in:
neuronal survival, synaptic plasticity, learning, memory, and adaptation to stress.
Selank-related research has explored neurotrophic signaling and changes in gene expression relevant to neuronal plasticity.
This area is particularly compelling because chronic stress and anxiety can alter neuroplasticity.
Researchers are therefore interested in whether neuropeptide signaling can influence both emotional state and the brain’s longer-term ability to adapt.
The evidence here is considerably more mechanistic than the clinical anxiety evidence, but it remains an important part of Selank research.
Selank & the Immune System
Selank’s immune effects are not an accidental side topic.
Remember that Selank was developed from tuftsin.
Tuftsin is naturally involved in immune regulation.
Researchers have therefore examined Selank’s effects on:
cytokines, chemokines, inflammatory signaling, and immune-cell activity.
Human research involving people with anxiety-asthenic disorders reported changes in cytokine balance during Selank treatment, while laboratory research has also demonstrated effects on cytokine-related gene expression.
This gives Selank an interesting neuroimmune research profile.
The Neuroimmune Connection
The nervous and immune systems are deeply interconnected.
Psychological stress can influence inflammation.
Inflammatory signals can affect mood and cognition.
Immune cells communicate with the brain.
Neuropeptides can influence both systems.
Selank provides researchers with an interesting way to study this relationship because its biological history bridges immune signaling and nervous-system regulation.
Rather than thinking about mental and immune health as completely separate systems, Selank research fits into the growing understanding that they continuously communicate.
Intranasal Research
Selank has historically been studied using intranasal administration.
The nasal cavity is an interesting route for neuropeptides because peptides taken orally can be rapidly degraded in the gastrointestinal tract.
Intranasal delivery may allow some molecules to be absorbed through nasal tissue and potentially access pathways relevant to the central nervous system.
This area is often called nose-to-brain delivery.
Actual absorption and brain exposure depend heavily on the specific peptide and formulation, so intranasal activity cannot simply be assumed for every related compound.
Still, Selank has an established history of intranasal research.
Selank vs. Benzodiazepines
Selank is frequently compared with benzodiazepines because of its anxiety research.
The mechanisms are not identical.
Benzodiazepines directly enhance GABA-A receptor activity through a well-characterized binding site.
Selank appears to influence the GABAergic system more indirectly and may act through regulatory or allosteric mechanisms.
The distinction matters because researchers have been interested in whether anxiety could be reduced without producing the same degree of:
sedation, cognitive impairment, tolerance, or dependence associated with chronic benzodiazepine exposure.
The existing studies are interesting, but Selank has not undergone the large international clinical-development programs required to establish that comparison definitively.
Selank vs. N-Acetyl Selank Amidate
Standard Selank is the better-studied molecule.
It consists of the original seven-amino-acid sequence:
Thr-Lys-Pro-Arg-Pro-Gly-Pro.
N-Acetyl Selank Amidate modifies both ends of that peptide in an attempt to potentially alter stability and duration.
Those modifications are scientifically plausible, but direct evidence for the modified analogue is much thinner.
So when discussing published human Selank research, it is important not to automatically transfer those results to N-Acetyl Selank Amidate.
For evidence strength:
Selank comes first.
The modified analogue remains a newer research question.
Selank vs. Semax
Selank and Semax are frequently paired because both emerged from Russian neuropeptide research.
Their areas of interest overlap considerably.
Selank is most strongly associated with:
anxiety, stress resilience, emotional regulation, cognition, and neuroimmune signaling.
Semax is more strongly associated with:
neuroprotection, cognition, memory, BDNF, neurological injury, and neurotrophic signaling.
A simplified way to think about them is:
Selank leans toward stress and anxiety regulation.
Semax leans toward cognition and neuroprotection.
But neither peptide is limited to those categories.
Evidence Snapshot
Human anxiety evidence: Meaningful but relatively small. Published clinical studies have investigated Selank in generalized anxiety and related disorders.
GABAergic research: Strong mechanistic interest, including animal, cell, receptor-binding, and gene-expression studies.
Enkephalin research: Experimental evidence supports effects on enzymes that degrade endogenous enkephalins.
Cognition and nootropic research: Promising experimental evidence, although the human evidence base is less extensive than modern approved cognitive medications.
Neuroimmune research: Meaningful mechanistic and limited human evidence involving cytokine and immune regulation.
Overall human evidence: More developed than many research peptides, but concentrated heavily in Russian literature and based on relatively small studies.
What Do We Know?
Selank is not just a peptide with a theoretical mechanism.
It has a genuine research history extending from molecular experiments to human clinical studies.
We know that it interacts with systems involving:
GABAergic neurotransmission, anxiety, enkephalins, gene expression, cognition, and immune signaling.
Small human studies have reported clinically measurable anxiolytic effects.
Experimental work gives researchers several plausible mechanisms for those effects.
That makes Selank one of the more scientifically interesting neuropeptides in the library.
What Are Researchers Still Trying to Determine?
The biggest missing piece is modern large-scale clinical validation.
Researchers would benefit from:
larger randomized trials, independent replication outside the original research groups, standardized formulations, pharmacokinetic studies, dose-response studies, long-term safety data, and direct comparison with established anxiety treatments.
Researchers also still need to determine exactly which mechanisms are most important.
Is Selank’s anxiety effect driven primarily by GABA modulation?
Enkephalins?
Changes in gene expression?
Neuroimmune signaling?
Or a combination of all of them?
The answer may ultimately be that Selank works precisely because it influences multiple regulatory systems.
Research & Regulatory Status
Selank is not an FDA-approved medication in the United States.
The FDA lists Selank as a recognized peptide substance in its substance-registration system, but the FDA specifically notes that having a UNII or substance record does not mean the substance has been reviewed or approved as a drug.
The FDA has also specifically identified Selank acetate in its information on bulk substances that may present significant safety risks in compounding. The agency cites concerns including peptide-related impurities, aggregation, potential immunogenicity, and a lack of important safety information regarding compounded Selank acetate exposure.
That regulatory concern does not erase Selank’s published research.
It means the biological evidence for the molecule and the quality or safety of an unapproved compounded product are two different questions.
Your Pep Resource Takeaway
Selank is one of the more compelling neuropeptides because its story extends well beyond the usual “calming peptide” description.
Its research connects:
anxiety, stress resilience, GABA, enkephalins, cognition, memory, gene expression, and immune signaling.
It also has something many experimental peptides lack—published human anxiety studies.
Those studies are small and deserve modern independent replication, but they give Selank a stronger clinical foundation than a compound supported entirely by animal research.
Perhaps the most interesting feature of Selank is that it does not appear to fit neatly into the traditional stimulant-versus-sedative model.
Researchers have instead explored whether it can regulate an excessive stress response while preserving cognition and normal function.
That makes Selank especially interesting for research into how the brain naturally controls anxiety rather than simply suppressing neural activity.
For researchers interested in anxiety, stress, GABA, cognition, memory, neuroplasticity, emotional regulation, neuroimmune signaling, and nootropic peptides, Selank remains one of the most noteworthy peptides in this category.
Research Areas / Search Keywords
Selank, Selank peptide, TP-7, TP7, Selank acetate, tuftsin analogue, tuftsin peptide, anxiety peptide, anxiety research, generalized anxiety disorder research, GAD research, stress peptide, stress resilience, stress response, calming peptide research, anxiolytic peptide, anxiolytic research, non-sedating anxiolytic, emotional regulation, mood research, GABA, GABAergic system, GABA-A receptor, GABAA, GABA modulation, allosteric modulation, benzodiazepine alternative research, Selank vs benzodiazepines, Selank vs phenazepam, Selank vs medazepam, enkephalin, enkephalinase, endogenous opioid peptide, cognition, cognitive function, nootropic peptide, memory research, learning research, focus research, concentration, brain fog research, neuropeptide, neuroplasticity, BDNF research, neurotransmitter research, serotonin research, monoamine signaling, gene expression, nervous system research, neuroimmune signaling, immune regulation, cytokines, chemokines, inflammation research, tuftsin, intranasal Selank, nasal peptide, nose-to-brain peptide, Selank vs Semax, Selank vs N-Acetyl Selank Amidate, N-Acetyl Selank, Russian peptide, experimental peptide, research peptide, peptide science.
Educational Disclaimer
This profile is provided for educational and research-information purposes only. Published research involving anxiety, cognition, neurotransmitter signaling, or immune regulation does not establish Selank as an FDA-approved treatment for anxiety or another medical condition in the United States. Human studies exist, but much of the clinical literature is relatively small and originates from Russian research programs. Unapproved or compounded Selank products should not be assumed to have the same identity, purity, safety, or performance as material used in published research.ing because of potential immunogenicity, peptide-impurity concerns, and insufficient safety information.